Both in Pharmaceuticals
Phathom Pharmaceuticals vs CytomX Therapeutics
Over the past year PHAT returned −35.0% and CTMX returned −14.9%; their daily moves had a correlation of 0.12.
PHAT −35.0% CTMX −14.9%Growth of $1, one year, split-adjusted
| Metric | PHAT | CTMX |
|---|---|---|
| Price | $7.36 | $2.75 |
| Market cap | $595.4M | $599.2M |
| Today | +0.14% | +2.23% |
| 1 month | −19.8% | −14.3% |
| 6 months | −30.1% | −37.6% |
| Year to date | −55.6% | −35.4% |
| 1 year | −37.5% | −5.2% |
| Revenue growth (YoY) | +88.0% | −92.4% |
| Gross margin | 79.7% | 100.0% |
| Net margin | −23.7% | −1457.4% |
| P/E (TTM) | — | — |
| Price / sales | 2.5× | 32.7× |
| Net cash | $16.5M | $330.3M |
| Dividend yield | — | — |
| Volatility (60d) | 80.9% | 60.5% |
| Short % of float | 18.1% | 19.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).